No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 718 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR What to Know About Navigating Cancer Care With a Disability: An... May 4, 2023 Man Who Lost His Mother to Breast Cancer Opens Resource Center... May 6, 2021 Self-care Isn’t Selfish August 25, 2021 Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 Load more HOT NEWS Female Representation at the Top of the Oncology Field Has Hit... FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... Breast-Cancer Mom Is Living On 84 Pence As She Fights For... Easing Concerns about Giving Research Study Participants Their Genetic Test Results
